nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—MTOR—cervical cancer	0.778	1	CbGaD
Temsirolimus—ABCB1—Topotecan—cervical cancer	0.0713	0.625	CbGbCtD
Temsirolimus—CYP3A4—Topotecan—cervical cancer	0.0427	0.375	CbGbCtD
Temsirolimus—Everolimus—MTOR—cervical cancer	0.00262	0.314	CrCbGaD
Temsirolimus—Pimecrolimus—MTOR—cervical cancer	0.00262	0.314	CrCbGaD
Temsirolimus—Mucosal inflammation—Topotecan—cervical cancer	0.0024	0.0561	CcSEcCtD
Temsirolimus—Febrile neutropenia—Topotecan—cervical cancer	0.00221	0.0516	CcSEcCtD
Temsirolimus—MTOR—epithelium—cervical cancer	0.00192	0.0515	CbGeAlD
Temsirolimus—Interstitial lung disease—Topotecan—cervical cancer	0.00188	0.0439	CcSEcCtD
Temsirolimus—Lung disorder—Topotecan—cervical cancer	0.00188	0.0439	CcSEcCtD
Temsirolimus—MTOR—renal system—cervical cancer	0.00178	0.0477	CbGeAlD
Temsirolimus—Pleural effusion—Topotecan—cervical cancer	0.00173	0.0405	CcSEcCtD
Temsirolimus—FKBP1A—epithelium—cervical cancer	0.00172	0.0463	CbGeAlD
Temsirolimus—MTOR—endometrium—cervical cancer	0.00172	0.0461	CbGeAlD
Temsirolimus—FKBP1A—uterine cervix—cervical cancer	0.00171	0.0459	CbGeAlD
Temsirolimus—MTOR—mammalian vulva—cervical cancer	0.00166	0.0446	CbGeAlD
Temsirolimus—FKBP1A—decidua—cervical cancer	0.00163	0.0437	CbGeAlD
Temsirolimus—FKBP1A—renal system—cervical cancer	0.0016	0.0429	CbGeAlD
Temsirolimus—MTOR—uterus—cervical cancer	0.00158	0.0425	CbGeAlD
Temsirolimus—Tacrolimus—MTOR—cervical cancer	0.00156	0.186	CrCbGaD
Temsirolimus—Sirolimus—MTOR—cervical cancer	0.00156	0.186	CrCbGaD
Temsirolimus—FKBP1A—endometrium—cervical cancer	0.00155	0.0415	CbGeAlD
Temsirolimus—Extravasation—Topotecan—cervical cancer	0.00152	0.0356	CcSEcCtD
Temsirolimus—FKBP1A—mammalian vulva—cervical cancer	0.0015	0.0401	CbGeAlD
Temsirolimus—FKBP1A—uterus—cervical cancer	0.00143	0.0382	CbGeAlD
Temsirolimus—MTOR—female reproductive system—cervical cancer	0.00142	0.0382	CbGeAlD
Temsirolimus—Blood bilirubin increased—Topotecan—cervical cancer	0.0014	0.0328	CcSEcCtD
Temsirolimus—Pulmonary embolism—Topotecan—cervical cancer	0.00133	0.0311	CcSEcCtD
Temsirolimus—MTOR—female gonad—cervical cancer	0.0013	0.0348	CbGeAlD
Temsirolimus—MTOR—vagina—cervical cancer	0.00129	0.0346	CbGeAlD
Temsirolimus—FKBP1A—female reproductive system—cervical cancer	0.00128	0.0344	CbGeAlD
Temsirolimus—Rash maculo-papular—Topotecan—cervical cancer	0.00121	0.0282	CcSEcCtD
Temsirolimus—FKBP1A—female gonad—cervical cancer	0.00117	0.0313	CbGeAlD
Temsirolimus—FKBP1A—vagina—cervical cancer	0.00116	0.0311	CbGeAlD
Temsirolimus—Sepsis—Topotecan—cervical cancer	0.00115	0.0269	CcSEcCtD
Temsirolimus—Dermatitis bullous—Topotecan—cervical cancer	0.00101	0.0236	CcSEcCtD
Temsirolimus—MTOR—Interferon type I signaling pathways—PIAS3—cervical cancer	0.000872	0.0435	CbGpPWpGaD
Temsirolimus—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000868	0.0203	CcSEcCtD
Temsirolimus—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00085	0.0199	CcSEcCtD
Temsirolimus—MTOR—lymph node—cervical cancer	0.000833	0.0224	CbGeAlD
Temsirolimus—Neutropenia—Topotecan—cervical cancer	0.000779	0.0182	CcSEcCtD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—PIAS3—cervical cancer	0.000752	0.0375	CbGpPWpGaD
Temsirolimus—FKBP1A—lymph node—cervical cancer	0.00075	0.0201	CbGeAlD
Temsirolimus—Pneumonia—Topotecan—cervical cancer	0.000747	0.0175	CcSEcCtD
Temsirolimus—CYP3A5—uterine cervix—cervical cancer	0.000745	0.02	CbGeAlD
Temsirolimus—Infestation—Topotecan—cervical cancer	0.000743	0.0174	CcSEcCtD
Temsirolimus—Infestation NOS—Topotecan—cervical cancer	0.000743	0.0174	CcSEcCtD
Temsirolimus—Stomatitis—Topotecan—cervical cancer	0.000724	0.0169	CcSEcCtD
Temsirolimus—Epistaxis—Topotecan—cervical cancer	0.000701	0.0164	CcSEcCtD
Temsirolimus—CYP3A5—renal system—cervical cancer	0.000697	0.0187	CbGeAlD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—WNT5A—cervical cancer	0.000692	0.0345	CbGpPWpGaD
Temsirolimus—Rhinitis—Topotecan—cervical cancer	0.000669	0.0156	CcSEcCtD
Temsirolimus—Pharyngitis—Topotecan—cervical cancer	0.000662	0.0155	CcSEcCtD
Temsirolimus—MTOR—mTOR signaling pathway—YY1—cervical cancer	0.000622	0.031	CbGpPWpGaD
Temsirolimus—Angiopathy—Topotecan—cervical cancer	0.000605	0.0141	CcSEcCtD
Temsirolimus—Immune system disorder—Topotecan—cervical cancer	0.000602	0.0141	CcSEcCtD
Temsirolimus—Mediastinal disorder—Topotecan—cervical cancer	0.000601	0.0141	CcSEcCtD
Temsirolimus—MTOR—SREBP signalling—YY1—cervical cancer	0.000601	0.03	CbGpPWpGaD
Temsirolimus—Chills—Topotecan—cervical cancer	0.000598	0.014	CcSEcCtD
Temsirolimus—Malnutrition—Topotecan—cervical cancer	0.00058	0.0136	CcSEcCtD
Temsirolimus—Back pain—Topotecan—cervical cancer	0.000562	0.0131	CcSEcCtD
Temsirolimus—Anaemia—Topotecan—cervical cancer	0.000537	0.0125	CcSEcCtD
Temsirolimus—Angioedema—Topotecan—cervical cancer	0.00053	0.0124	CcSEcCtD
Temsirolimus—CYP3A4—renal system—cervical cancer	0.000523	0.014	CbGeAlD
Temsirolimus—Leukopenia—Topotecan—cervical cancer	0.00052	0.0121	CcSEcCtD
Temsirolimus—CYP2D6—renal system—cervical cancer	0.000514	0.0138	CbGeAlD
Temsirolimus—CYP3A5—female gonad—cervical cancer	0.000508	0.0136	CbGeAlD
Temsirolimus—Cough—Topotecan—cervical cancer	0.000507	0.0118	CcSEcCtD
Temsirolimus—CYP3A5—vagina—cervical cancer	0.000505	0.0135	CbGeAlD
Temsirolimus—Myalgia—Topotecan—cervical cancer	0.000494	0.0116	CcSEcCtD
Temsirolimus—Chest pain—Topotecan—cervical cancer	0.000494	0.0116	CcSEcCtD
Temsirolimus—Arthralgia—Topotecan—cervical cancer	0.000494	0.0116	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.000491	0.0115	CcSEcCtD
Temsirolimus—Anaphylactic shock—Topotecan—cervical cancer	0.000474	0.0111	CcSEcCtD
Temsirolimus—Infection—Topotecan—cervical cancer	0.000471	0.011	CcSEcCtD
Temsirolimus—MTOR—Regulation of Telomerase—UBE3A—cervical cancer	0.000467	0.0233	CbGpPWpGaD
Temsirolimus—Nervous system disorder—Topotecan—cervical cancer	0.000465	0.0109	CcSEcCtD
Temsirolimus—Thrombocytopenia—Topotecan—cervical cancer	0.000464	0.0108	CcSEcCtD
Temsirolimus—Skin disorder—Topotecan—cervical cancer	0.00046	0.0108	CcSEcCtD
Temsirolimus—Anorexia—Topotecan—cervical cancer	0.000452	0.0106	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000432	0.0101	CcSEcCtD
Temsirolimus—Dyspnoea—Topotecan—cervical cancer	0.000422	0.00988	CcSEcCtD
Temsirolimus—CYP3A4—female reproductive system—cervical cancer	0.000419	0.0112	CbGeAlD
Temsirolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—cervical cancer	0.000414	0.0207	CbGpPWpGaD
Temsirolimus—CYP2D6—female reproductive system—cervical cancer	0.000412	0.0111	CbGeAlD
Temsirolimus—Decreased appetite—Topotecan—cervical cancer	0.000412	0.00963	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Topotecan—cervical cancer	0.000409	0.00956	CcSEcCtD
Temsirolimus—Fatigue—Topotecan—cervical cancer	0.000408	0.00955	CcSEcCtD
Temsirolimus—Constipation—Topotecan—cervical cancer	0.000405	0.00947	CcSEcCtD
Temsirolimus—Pain—Topotecan—cervical cancer	0.000405	0.00947	CcSEcCtD
Temsirolimus—ABCB1—epithelium—cervical cancer	0.000399	0.0107	CbGeAlD
Temsirolimus—ABCB1—uterine cervix—cervical cancer	0.000396	0.0106	CbGeAlD
Temsirolimus—Gastrointestinal pain—Topotecan—cervical cancer	0.000387	0.00906	CcSEcCtD
Temsirolimus—ABCB1—decidua—cervical cancer	0.000377	0.0101	CbGeAlD
Temsirolimus—CYP2D6—female gonad—cervical cancer	0.000375	0.0101	CbGeAlD
Temsirolimus—Abdominal pain—Topotecan—cervical cancer	0.000375	0.00876	CcSEcCtD
Temsirolimus—Body temperature increased—Topotecan—cervical cancer	0.000375	0.00876	CcSEcCtD
Temsirolimus—ABCB1—renal system—cervical cancer	0.00037	0.00993	CbGeAlD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—PIAS3—cervical cancer	0.000362	0.0181	CbGpPWpGaD
Temsirolimus—ABCB1—endometrium—cervical cancer	0.000358	0.0096	CbGeAlD
Temsirolimus—Hypersensitivity—Topotecan—cervical cancer	0.000349	0.00816	CcSEcCtD
Temsirolimus—ABCB1—mammalian vulva—cervical cancer	0.000346	0.00929	CbGeAlD
Temsirolimus—FKBP1A—TOR Signaling—MTOR—cervical cancer	0.000346	0.0173	CbGpPWpGaD
Temsirolimus—Asthenia—Topotecan—cervical cancer	0.00034	0.00795	CcSEcCtD
Temsirolimus—Pruritus—Topotecan—cervical cancer	0.000335	0.00784	CcSEcCtD
Temsirolimus—ABCB1—uterus—cervical cancer	0.00033	0.00885	CbGeAlD
Temsirolimus—Diarrhoea—Topotecan—cervical cancer	0.000324	0.00758	CcSEcCtD
Temsirolimus—Dizziness—Topotecan—cervical cancer	0.000313	0.00733	CcSEcCtD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—WNT5A—cervical cancer	0.000304	0.0151	CbGpPWpGaD
Temsirolimus—Vomiting—Topotecan—cervical cancer	0.000301	0.00704	CcSEcCtD
Temsirolimus—Rash—Topotecan—cervical cancer	0.000299	0.00698	CcSEcCtD
Temsirolimus—Dermatitis—Topotecan—cervical cancer	0.000298	0.00698	CcSEcCtD
Temsirolimus—Headache—Topotecan—cervical cancer	0.000297	0.00694	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000296	0.0148	CbGpPWpGaD
Temsirolimus—ABCB1—female reproductive system—cervical cancer	0.000296	0.00795	CbGeAlD
Temsirolimus—MTOR—IL2 signaling events mediated by PI3K—TERT—cervical cancer	0.000295	0.0147	CbGpPWpGaD
Temsirolimus—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000286	0.0142	CbGpPWpGaD
Temsirolimus—Nausea—Topotecan—cervical cancer	0.000281	0.00658	CcSEcCtD
Temsirolimus—MTOR—Costimulation by the CD28 family—HLA-DPB1—cervical cancer	0.000279	0.0139	CbGpPWpGaD
Temsirolimus—ABCB1—female gonad—cervical cancer	0.00027	0.00724	CbGeAlD
Temsirolimus—ABCB1—vagina—cervical cancer	0.000268	0.00719	CbGeAlD
Temsirolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—cervical cancer	0.00023	0.0115	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling—CTNNB1—cervical cancer	0.000229	0.0114	CbGpPWpGaD
Temsirolimus—MTOR—IL12-mediated signaling events—CD8A—cervical cancer	0.000225	0.0112	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—CTNNB1—cervical cancer	0.000222	0.0111	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—cervical cancer	0.000218	0.0109	CbGpPWpGaD
Temsirolimus—MTOR—VEGFR2 mediated vascular permeability—CTNNB1—cervical cancer	0.000211	0.0105	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—CTNNB1—cervical cancer	0.0002	0.00996	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000198	0.00985	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—STAT3—cervical cancer	0.000193	0.00965	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—TERT—cervical cancer	0.000181	0.00904	CbGpPWpGaD
Temsirolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000176	0.00878	CbGpPWpGaD
Temsirolimus—ABCB1—lymph node—cervical cancer	0.000173	0.00465	CbGeAlD
Temsirolimus—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000169	0.00845	CbGpPWpGaD
Temsirolimus—MTOR—PI3K Cascade—FGFR3—cervical cancer	0.000166	0.0083	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—cervical cancer	0.000158	0.00789	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—CA9—cervical cancer	0.000151	0.00755	CbGpPWpGaD
Temsirolimus—MTOR—IRS-mediated signalling—FGFR3—cervical cancer	0.000139	0.00694	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—cervical cancer	0.000138	0.00688	CbGpPWpGaD
Temsirolimus—MTOR—ErbB2/ErbB3 signaling events—STAT3—cervical cancer	0.000136	0.00676	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events—FGFR3—cervical cancer	0.000135	0.00675	CbGpPWpGaD
Temsirolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—cervical cancer	0.000134	0.00669	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—AKAP13—cervical cancer	0.000132	0.00658	CbGpPWpGaD
Temsirolimus—MTOR—IGF1R signaling cascade—FGFR3—cervical cancer	0.000131	0.00652	CbGpPWpGaD
Temsirolimus—MTOR—Insulin receptor signalling cascade—FGFR3—cervical cancer	0.000131	0.00652	CbGpPWpGaD
Temsirolimus—MTOR—IFN-gamma pathway—STAT3—cervical cancer	0.00013	0.00651	CbGpPWpGaD
Temsirolimus—MTOR—IL12-mediated signaling events—CD4—cervical cancer	0.000129	0.00644	CbGpPWpGaD
Temsirolimus—MTOR—Wnt Signaling Pathway Netpath—CTNNB1—cervical cancer	0.000129	0.00642	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—FGFR3—cervical cancer	0.000124	0.0062	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—CASP3—cervical cancer	0.000123	0.00614	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—STAT3—cervical cancer	0.000122	0.00606	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—FGFR3—cervical cancer	0.000121	0.00605	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—FGFR3—cervical cancer	0.00012	0.006	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—cervical cancer	0.000118	0.00586	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—CD4—cervical cancer	0.000117	0.00583	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—CASP3—cervical cancer	0.000112	0.00557	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000111	0.00552	CbGpPWpGaD
Temsirolimus—MTOR—Interferon type I signaling pathways—STAT3—cervical cancer	0.000109	0.00543	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by Insulin receptor—FGFR3—cervical cancer	0.000109	0.00541	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000107	0.00532	CbGpPWpGaD
Temsirolimus—MTOR—CDC42 signaling events—CTNNB1—cervical cancer	0.000101	0.00506	CbGpPWpGaD
Temsirolimus—MTOR—IL12-mediated signaling events—STAT3—cervical cancer	0.0001	0.00499	CbGpPWpGaD
Temsirolimus—MTOR—LKB1 signaling events—TP53—cervical cancer	9.96e-05	0.00497	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—EGFR—cervical cancer	9.88e-05	0.00493	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—CD4—cervical cancer	9.86e-05	0.00492	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—EGFR—cervical cancer	9.4e-05	0.00469	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—cervical cancer	9.38e-05	0.00468	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—FGFR3—cervical cancer	9.28e-05	0.00463	CbGpPWpGaD
Temsirolimus—MTOR—TSH signaling pathway—STAT3—cervical cancer	9.26e-05	0.00462	CbGpPWpGaD
Temsirolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—cervical cancer	9.11e-05	0.00455	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—cervical cancer	8.88e-05	0.00443	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	8.76e-05	0.00437	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—FGFR3—cervical cancer	8.74e-05	0.00436	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	8.38e-05	0.00418	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—STAT3—cervical cancer	8.36e-05	0.00417	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—FGFR3—cervical cancer	8.35e-05	0.00416	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	8.32e-05	0.00415	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—FGFR3—cervical cancer	8.31e-05	0.00414	CbGpPWpGaD
Temsirolimus—MTOR—ErbB Signaling Pathway—TP53—cervical cancer	8.3e-05	0.00414	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—FGFR3—cervical cancer	8.27e-05	0.00412	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—FGFR3—cervical cancer	8.23e-05	0.0041	CbGpPWpGaD
Temsirolimus—MTOR—Regulation of Telomerase—EGFR—cervical cancer	8.22e-05	0.0041	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—WNT2—cervical cancer	8.2e-05	0.00409	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—UBE3A—cervical cancer	8.11e-05	0.00405	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cervical cancer	8.11e-05	0.00404	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	8.07e-05	0.00403	CbGpPWpGaD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	7.99e-05	0.00399	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—TP53—cervical cancer	7.9e-05	0.00394	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	7.74e-05	0.00386	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—FGFR3—cervical cancer	7.74e-05	0.00386	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—FGFR3—cervical cancer	7.74e-05	0.00386	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—FGFR3—cervical cancer	7.67e-05	0.00383	CbGpPWpGaD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	7.64e-05	0.00381	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—STAT3—cervical cancer	7.64e-05	0.00381	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—cervical cancer	7.6e-05	0.00379	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—FGFR3—cervical cancer	7.57e-05	0.00378	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	7.51e-05	0.00375	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TAAR6—cervical cancer	7.35e-05	0.00367	CbGpPWpGaD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	7.22e-05	0.0036	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	7.18e-05	0.00358	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—FGFR3—cervical cancer	7.16e-05	0.00357	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—TP53—cervical cancer	7.16e-05	0.00357	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	6.85e-05	0.00342	CbGpPWpGaD
Temsirolimus—MTOR—AMPK Signaling—TP53—cervical cancer	6.82e-05	0.0034	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—CTNNB1—cervical cancer	6.81e-05	0.0034	CbGpPWpGaD
Temsirolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—cervical cancer	6.81e-05	0.0034	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	6.4e-05	0.00319	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—STAT3—cervical cancer	6.39e-05	0.00319	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—WNT5A—cervical cancer	6.21e-05	0.0031	CbGpPWpGaD
Temsirolimus—MTOR—PI-3K cascade—EGFR—cervical cancer	6.14e-05	0.00306	CbGpPWpGaD
Temsirolimus—MTOR—PI3K/AKT activation—EGFR—cervical cancer	5.99e-05	0.00299	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—EGFR—cervical cancer	5.94e-05	0.00297	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—CASP3—cervical cancer	5.91e-05	0.00295	CbGpPWpGaD
Temsirolimus—MTOR—ErbB1 downstream signaling—EGFR—cervical cancer	5.81e-05	0.0029	CbGpPWpGaD
Temsirolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	5.81e-05	0.0029	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—WNT2—cervical cancer	5.74e-05	0.00286	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—CTNNB1—cervical cancer	5.69e-05	0.00284	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	5.69e-05	0.00284	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	5.48e-05	0.00273	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—CASP8—cervical cancer	5.43e-05	0.00271	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	5.37e-05	0.00268	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—FGFR3—cervical cancer	5.27e-05	0.00263	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—STAT3—cervical cancer	5.05e-05	0.00252	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—AKAP13—cervical cancer	5.04e-05	0.00251	CbGpPWpGaD
Temsirolimus—MTOR—BDNF signaling pathway—STAT3—cervical cancer	4.96e-05	0.00248	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—UBE3A—cervical cancer	4.92e-05	0.00245	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TP53—cervical cancer	4.88e-05	0.00243	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-DPB1—cervical cancer	4.84e-05	0.00242	CbGpPWpGaD
Temsirolimus—MTOR—Disease—WNT2—cervical cancer	4.61e-05	0.0023	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by SCF-KIT—EGFR—cervical cancer	4.59e-05	0.00229	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—STAT3—cervical cancer	4.54e-05	0.00226	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	4.52e-05	0.00225	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling of activated FGFR—EGFR—cervical cancer	4.39e-05	0.00219	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—WNT5A—cervical cancer	4.35e-05	0.00217	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	4.34e-05	0.00217	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB4—EGFR—cervical cancer	4.32e-05	0.00215	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—STAT3—cervical cancer	4.21e-05	0.0021	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TAAR6—cervical cancer	4.14e-05	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signal transduction—EGFR—cervical cancer	4.12e-05	0.00206	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—STAT3—cervical cancer	4.11e-05	0.00205	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—CASP3—cervical cancer	4.11e-05	0.00205	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR—EGFR—cervical cancer	4.1e-05	0.00205	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	4.1e-05	0.00205	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by ERBB2—EGFR—cervical cancer	4.08e-05	0.00204	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 signaling—EGFR—cervical cancer	4.06e-05	0.00203	CbGpPWpGaD
Temsirolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	4.01e-05	0.002	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by FGFR in disease—EGFR—cervical cancer	3.82e-05	0.00191	CbGpPWpGaD
Temsirolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	3.82e-05	0.00191	CbGpPWpGaD
Temsirolimus—MTOR—DAP12 interactions—EGFR—cervical cancer	3.82e-05	0.00191	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—EGFR—cervical cancer	3.79e-05	0.00189	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-DQB1—cervical cancer	3.78e-05	0.00189	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—EGFR—cervical cancer	3.76e-05	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by PDGF—EGFR—cervical cancer	3.74e-05	0.00187	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	3.73e-05	0.00186	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—TP53—cervical cancer	3.65e-05	0.00182	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—HES1—cervical cancer	3.58e-05	0.00178	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—EGFR—cervical cancer	3.54e-05	0.00177	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD8A—cervical cancer	3.53e-05	0.00176	CbGpPWpGaD
Temsirolimus—MTOR—Disease—WNT5A—cervical cancer	3.49e-05	0.00174	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—CASP3—cervical cancer	3.41e-05	0.0017	CbGpPWpGaD
Temsirolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	3.39e-05	0.00169	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—WNT2—cervical cancer	3.23e-05	0.00161	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MTHFR—cervical cancer	3.14e-05	0.00157	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TERT—cervical cancer	3.13e-05	0.00156	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—STAT3—cervical cancer	3.06e-05	0.00152	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOTCH2—cervical cancer	3.05e-05	0.00152	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—FGFR3—cervical cancer	3.01e-05	0.0015	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-DPB1—cervical cancer	2.94e-05	0.00147	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—FGFR3—cervical cancer	2.89e-05	0.00144	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CA9—cervical cancer	2.88e-05	0.00144	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—FGFR3—cervical cancer	2.87e-05	0.00143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—STAT3—cervical cancer	2.87e-05	0.00143	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—AKAP13—cervical cancer	2.83e-05	0.00141	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOTCH1—cervical cancer	2.7e-05	0.00135	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	2.68e-05	0.00134	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by NGF—EGFR—cervical cancer	2.6e-05	0.0013	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CASP8—cervical cancer	2.57e-05	0.00128	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—HES1—cervical cancer	2.5e-05	0.00125	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—WNT5A—cervical cancer	2.45e-05	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—Cellular responses to stress—TP53—cervical cancer	2.33e-05	0.00116	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-DQB1—cervical cancer	2.29e-05	0.00114	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TERT—cervical cancer	2.19e-05	0.00109	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD8A—cervical cancer	2.14e-05	0.00107	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CD4—cervical cancer	2.11e-05	0.00105	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CA9—cervical cancer	2.08e-05	0.00104	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	2.03e-05	0.00101	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD4—cervical cancer	2.03e-05	0.00101	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—MTOR—cervical cancer	2.02e-05	0.00101	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CD4—cervical cancer	2.02e-05	0.00101	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—FGFR3—cervical cancer	2.01e-05	0.001	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HES1—cervical cancer	2.01e-05	0.001	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	1.96e-05	0.000975	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOTCH1—cervical cancer	1.89e-05	0.000943	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CTNNB1—cervical cancer	1.88e-05	0.000936	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CTNNB1—cervical cancer	1.79e-05	0.000895	CbGpPWpGaD
Temsirolimus—MTOR—Disease—MTHFR—cervical cancer	1.77e-05	0.000882	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TERT—cervical cancer	1.76e-05	0.000879	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—FGFR3—cervical cancer	1.75e-05	0.000874	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH2—cervical cancer	1.72e-05	0.000857	CbGpPWpGaD
Temsirolimus—MTOR—Disease—FGFR3—cervical cancer	1.62e-05	0.000807	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CA9—cervical cancer	1.57e-05	0.000783	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—STAT3—cervical cancer	1.56e-05	0.00078	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	1.55e-05	0.000773	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOTCH1—cervical cancer	1.52e-05	0.000757	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CASP8—cervical cancer	1.5e-05	0.000747	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—EGFR—cervical cancer	1.49e-05	0.000741	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CA9—cervical cancer	1.48e-05	0.000738	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—EGFR—cervical cancer	1.43e-05	0.000712	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—EGFR—cervical cancer	1.42e-05	0.000709	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MTOR—cervical cancer	1.42e-05	0.000707	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HES1—cervical cancer	1.41e-05	0.000703	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CASP3—cervical cancer	1.3e-05	0.00065	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	1.3e-05	0.000649	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CTNNB1—cervical cancer	1.26e-05	0.000626	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TERT—cervical cancer	1.23e-05	0.000616	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD4—cervical cancer	1.23e-05	0.000614	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—MTHFR—cervical cancer	1.17e-05	0.000583	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD4—cervical cancer	1.14e-05	0.000566	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—FGFR3—cervical cancer	1.13e-05	0.000565	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—STAT3—cervical cancer	1.09e-05	0.000546	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CTNNB1—cervical cancer	1.09e-05	0.000545	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOTCH1—cervical cancer	1.06e-05	0.00053	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CTNNB1—cervical cancer	1.01e-05	0.000503	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EGFR—cervical cancer	9.95e-06	0.000496	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CA9—cervical cancer	9.67e-06	0.000483	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—STAT3—cervical cancer	9.52e-06	0.000475	CbGpPWpGaD
Temsirolimus—MTOR—Disease—STAT3—cervical cancer	8.79e-06	0.000439	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—EGFR—cervical cancer	8.65e-06	0.000432	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—MTHFR—cervical cancer	8.44e-06	0.000421	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TP53—cervical cancer	8.35e-06	0.000417	CbGpPWpGaD
Temsirolimus—MTOR—Disease—EGFR—cervical cancer	7.99e-06	0.000399	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CASP3—cervical cancer	7.33e-06	0.000366	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CTNNB1—cervical cancer	7.06e-06	0.000352	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—MTHFR—cervical cancer	6.37e-06	0.000318	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—STAT3—cervical cancer	6.16e-06	0.000307	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—MTHFR—cervical cancer	6e-06	0.000299	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EGFR—cervical cancer	5.59e-06	0.000279	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TP53—cervical cancer	4.7e-06	0.000234	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—MTHFR—cervical cancer	3.92e-06	0.000196	CbGpPWpGaD
